Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, a number of monotherapy and combinatorial strategies have FDA-approved indications. Increasing evidence is also supporting the use of immunotherapies in locally advanced and earlier disease settings of NSCLC. More recently, the immunotherapy era has arrived in SCLC, where other novel therapies such as transcription inhibitors are also showing promise.
In this series of activities, leading experts review the newest practice-changing data and relevant implications for modern management of patients with lung cancer. Findings from patient surveys are integrated throughout the evidence reviews, as are case scenarios to illustrate how to navigate the complex treatment landscape in NSCLC and SCLC and make well-informed, shared decisions with patients aligned with their needs and preferences.
This series of activities has been designed to meet the educational needs of oncologists and other clinicians involved in the management of lung cancer.
Suresh S. Ramalingam, MD, FACP, FASCO
Suresh S. Ramalingam, MD, FACP, FASCO, will be joined by Hossein Borghaei, DO, MS, and Leora Horn, MD, MSc, FRCPC, as expert presenters for this educational activity.
Suresh S. Ramalingam, MD, FACP, FASCO
Suresh S. Ramalingam, MD, FACP, FASCO, Hossein Borghaei, DO, MS, and Leora Horn, MD, MSc, FRCPC
This educational curriculum is supported through educational grants from Bristol Myers Squibb, Jazz Pharmaceuticals, Inc., and Merck & Co., Inc.
